Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC585 Phase 1 Safety, PK, and Food Effect Study
NCT04512170Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jul 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of yifenidone in idiopathic pulmonary fibrosis (IPF) (6 arms), sponsored by Sunshine Lake Pharma. Primary endpoint: Adverse Events up to 18 days. Started Jul 2020; status: completed.
02
Drugs
yifenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04512170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04512170.